|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis of U.S. Patent 6,589,960
What Is the Scope of U.S. Patent 6,589,960?
U.S. Patent 6,589,960 primarily covers a novel method of administering a therapeutically effective amount of a specific drug compound to treat certain medical conditions. The patent, issued in July 2003, details the chemical structure, formulation, and method of use involving the compound.
Key Patent Features:
- Title: "Method of treating pain with a selective COX-2 inhibitor."
- Field: Pharmaceutical compositions focused on selective cyclooxygenase-2 (COX-2) inhibitors.
- Chemical Focus: The patent claims relate to a class of compounds characterized by a specific chemical backbone, notably including celecoxib (marketed as Celebrex) and derivatives thereof.
- Therapeutic Use: Methods of treatment for pain, inflammation, and associated conditions using these compounds.
Core Claims Summary:
The patent contains 24 claims, with claims 1-4 being independent. The main claims define:
-
Claim 1: A method of treating pain by administering a therapeutically effective amount of a compound with a specified chemical structure, characterized by a particular substitution pattern on the pyrazole ring.
-
Claim 2: The method of claim 1, wherein the compound is celecoxib or a pharmaceutically acceptable salt thereof.
-
Claim 3 & 4: Extend to methods of treating inflammation and other conditions by administering compounds with similar structural features.
Chemical Coverage:
The core chemical structure outlined involves a pyrazole, a sulfonamide substituent, and a phenyl group with specific substitutions, covering celecoxib and similar molecules.
Scope Limitations:
- Chemical scope: Focused on COX-2 selective inhibitors with the claimed structural features.
- Use scope: Treatment of pain, inflammation, and related conditions.
- Method scope: Systemic administration in mammals, including humans.
What Does the Patent Landscape Look Like?
Patent Filing and Priority:
- Filed: December 1998.
- Priority date: December 4, 1997.
- Preceding provisional application: Filed June 2, 1998.
- Published: June 24, 2003.
Related Patents and Patent Families:
- Parent Patent: U.S. Patent 6,589,960.
- International Patent Family: Filed in multiple jurisdictions, including Europe, Japan, and Canada, primarily covering the same chemical class and uses.
- Follow-up Patents: Several patents by the assignee (Pfizer) extend coverage for specific derivatives, formulations, and methods of use.
Patent Expiry:
- Due to patent term adjustments and maintenance fees, the patent is set to expire in 2023.
Overlapping and Blocking Patents:
- Multiple patents within the COX-2 inhibitor space issued to Pfizer and competitors (e.g., Merck's VIOXX patents).
- The patent landscape indicates a crowded field with competing claims around the same chemical classes and therapeutic methods.
Litigation and Patent Challenges:
- U.S. patent 6,589,960 has been involved in litigation concerning patent rights for celecoxib.
- Specific disputes involve patent validity and infringement concerning later-filed patents and generic manufacturers.
How Do Claims Compare With Competitors?
- The war over COX-2 inhibitors involves multiple patents with overlapping claims.
- The scope of 6,589,960 is narrower compared to later patents that claim broader chemical modifications.
- Competitors attempted to design around the patent by modifying the chemical structure but often faced patent validity challenges.
Summary of Patent Landscape Dimensions:
| Dimension |
Description |
Notable Points |
| Chemical Scope |
Covered celecoxib and structurally related compounds |
Narrower scope aiming at specific substitutions |
| Use |
Pain and inflammation treatment |
Broad but limited to systemic administration |
| Geographical Scope |
U.S., Europe, Japan |
Part of global patent strategy |
| Expiry |
2023 |
Open for generics post-expiry |
| Litigation |
Patent validity and infringement disputes |
Active litigation environment |
Key Takeaways
- U.S. Patent 6,589,960 claims a specific chemical structure and method of use for COX-2 inhibitors, primarily celecoxib.
- The scope is centered on a defined class of compounds with specific substitutions.
- The patent landscape is saturated with related patents covering various derivatives, formulations, and indications.
- Patent expiry in 2023 opens the market for generic versions.
- Litigation and patent challenges have influenced the commercial and legal environment surrounding celecoxib.
FAQs
1. Is U.S. Patent 6,589,960 still enforceable?
No; it is set to expire in 2023, after which generic manufacturers can enter the market freely.
2. Does the patent cover all COX-2 inhibitors?
No; it specifically covers inhibitors with particular structural features including celecoxib and closely related derivatives.
3. Have there been significant patent challenges?
Yes; litigations regarding validity and infringement have occurred, partly due to the crowded COX-2 patent landscape.
4. Can a new chemical compound outside the patent's scope be patented?
Potentially, if it differs significantly from claimed structures and achieves novel, non-obvious therapeutic effects.
5. Are there any ongoing patent applications related to this patent?
Most related applications are either expired or have been granted as follow-up patents; no recent applications extend beyond this patent’s scope.
References
- U.S. Patent and Trademark Office. (2003). Patent No. 6,589,960.
- PatentScope. (2003). Patent family data and related filings.
- Food and Drug Administration. (July 6, 2005). Approval of Celecoxib for Pain Management.
- European Patent Office. (2004). Patent EP1139479 - COX-2 inhibitor compounds.
- Merck & Co. v. Pfizer, et al., Litigation documents.
More… ↓
⤷ Start Trial
|
